<DOC>
	<DOCNO>NCT02301364</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , Buparlisib ( also know BKM120 ) lymphoma central nervous system .</brief_summary>
	<brief_title>Buparlisib ( BKM120 ) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma ( PCNSL ) Recurrent/Refractory Secondary Central Nervous System Lymphoma ( SCNSL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neurologic Manifestations</mesh_term>
	<criteria>Participants must able understand willing sign write informed consent document . Subjects must least 18 year age day consent study . Histologically document PCNSL SCNSL . Patients SCNSL need cytology tissue biopsy document lymphomatous involvement CNS Patients must relapsed/refractory PCNSL relapsed/refractory SCNSL All patient need receive least one prior CNS direct therapy . There restriction number recurrence . Patients parenchymal lesion must unequivocal evidence disease progression imaging ( MRI brain head CT ) 21 day prior study registration . For patient leptomeningeal disease , CSF cytology must document lymphoma cell and/or image finding consistent CSF disease 21 day prior study registration . Participants must Karnofsky performance status ( KPS ) ≥ 50 . Participants must adequate bone marrow organ function show : Absolute neutrophil count ( ANC ) ≥ 1.5x 109/L Platelets ≥ 100 x 109/L platelet transfusion within past 14 day prior study registration Hemoglobin ( Hgb ) ≥ 9 g/dL red blood cell ( RBC ) transfusion within past 14 day prior study registration International Normalized Ratio ( INR ) ≤ 1.5 Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 1.5 time ULN . Serum bilirubin ≤ upper limit normal ; total bilirubin ≤ 2.0x ULN direct bilirubin within normal range patient well document Gilbert Syndrome . Participants must able take oral medication . Patients must able tolerate MRI scan . Patients must able tolerate lumbar puncture and/or Ommaya tap . Participants must recover grade 1 toxicity prior therapy . Participates must able submit 20 unstained slide initial tissue diagnosis confirmation diagnosis correlative study Life expectancy &gt; 3 month ( opinion investigator ) Note : Prior autologous stem cell transplant well radiation CNS NOT exclusion criterion . Prior allogenic stem cell transplant IS exclusion criterion . Patients SCNSL actively receive treatment extraCNS disease exclude . Patient complete resolution systemic disease require additional systemic therapy ( e.g . maintenance rituximab decadron ) . The patient receive prior treatment PI3K inhibitor , AKT inhibitor , mTOR inhibitor ( e.g . rapamycin , MK2206 , perifosine , etc. ) . Patient concurrently use approve investigational antineoplastic agent Patient receive chemotherapy target anticancer therapy , monoclonal antibody ≤ 4 week 5 halflives , whichever short , 6 week nitrosourea mitomycinC prior start study drug , patient recover side side effect therapy Patient receive wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug recover grade 1 well related side effect therapy ( except alopecia ) Patient require 8 mg dexamethasone daily equivalent Patient take enzyme induce antiepileptic drug ( EIAED ) , include phenobarbital , phenytoin , fosphenytoin , primidone , carbamazepine , oxcarbazepine , eslicarbazepine , rufinamide , felbamate . Participates must EIAED least two week prior start study drug Patient take drug know strong inhibitor inducer isoenzyme CYP3A . Participants must strong CYP3A inhibitor inducer least two week prior start study drug . Patient take drug know risk promote QT prolongation Torsade de Pointes Patient currently use herbal preparation medication . Participants stop use herbal medication 7 day prior first dose study drug . Patient use warfarin Coumadinderivative anticoagulant . Patients must Coumadinderivative anticoagulant least seven day prior start study drug . Low molecular weight heparin allow Patient history allergic reaction compound similar chemical biological composition buparlisib Patient uncontrolled intercurrent illness , include , limited , ongoing active infection , chronic liver disease , chronic renal disease , pancreatitis , chronic pulmonary disease , psychiatric illness social situation would limit compliance study requirement Patient acute viral hepatitis history chronic active HBV HCV infection Patient active concurrent malignancy require active therapy . Patient known human immunodeficiency virus ( HIV ) infection Patient severe psychiatric disease would interfere participation trial determine study investigator Patient ≥ CTCAE grade 3 anxiety Patient ≥ CTCAE grade 2 diarrhea Patient score ≥12 PHQ9 questionnaire Patient select response `` 1 , 2 3 '' question number 9 PHQ9questionaire regard potential suicidal thought ideation ( independent total score PHQ9 ) . Patient GAD7 mood scale score ≥15 . Patient medically document history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) . Patient active cardiac disease cardiac dysfunction include follow : Left ventricular ejection fraction ( LVEF ) ,50 % determined Multiple Gated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) QTc &gt; 480msec screen ECG ( use QTcF formula ) Angina pectoris require use antianginal medication Ventricular arrhythmias except benign premature ventricular contraction Supraventricular nodal arrhythmia require pacemaker control medication Conduction abnormality require pacemaker Valvular disease document compromise cardiac function Symptomatic pericarditis Myocardial infarction within last 6 month , document persistent elevated cardiac enzyme persistent regional wall motion abnormality assessment leave ventricular ejection fraction function History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Congenital long QT syndrome Patient currently receive treatment QT prolong medication know risk induce Torsades de Pointes , treatment discontinue switched different medication prior start study drug . Patient impair gastrointestinal function gastrointestinal disease affect absorption buparlisib ( e.g . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , extensive small bowel resection ) . Patient poorly control diabetes mellitus glycosylated hemoglobin &gt; 8 % poorly control steroidinduced diabetes mellitus glycosylated hemoglobin &gt; 8 % . Patient underwent major systemic surgery ≤ 2 week prior start trial treatment recover side effect surgery . Women pregnant nursing ( lactate ) , pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test &gt; 5 mIU/mL . Patients receive allogenic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Buparlisib ( BKM120 )</keyword>
	<keyword>14-177</keyword>
</DOC>